Bluepharma | Universidade de Coimbra Innovation Award

Bluepharma | University of Coimbra Innovation Award is attributed every 2 years to an innovative research project in Health Sciences area. The application is open to Portuguese Researchers from National or Foreign laboratories, institutes and organizations developing innovative research in Health Sciences. This Award is intended to distinguish merit, originality and relevance of scientific projects that may impact future societies and/or the scientific community.

The winner of the Bluepharma | University of Coimbra Innovation Award 2019 is the scientific project
"Human Protein based platforms for 3D cell culture and development of microtissues for drug screening"

 

Award Date: January 13 and March 16, 2018

Development: João Mano, Catarina Custódio, Sara Santos, Cátia Monteiro and Inês Deus from Departament of Chemistry, CICECO - Aveiro Institute of Materials, University of Aveiro

 

O projeto foca-se no desenvolvimento de microambientes in vitro, que fornecem às células sinais bioquímicos e mecânicos que fazem parte de seu ambiente natural. Isto é conseguido através da manipulação de proteínas isoladas do plasma sanguíneo ou de tecidos perinatais para preparar uma nova geração de hidrogéis com propriedades mecânicas controladas capazes de encapsular praticamente qualquer tipo de célula. As matérias-primas, usadas neste projeto, derivadas de dadores humanos são facilmente acessíveis sem causar morbidade no local doador. Esta tecnologia inovadora de microtecidos 3D humanizados abre uma série de possibilidades para o estudo de doenças e medicina personalizada e, portanto, abordagens terapêuticas direcionadas com alto potencial clínico e de translação.

Read more at Bluepharma News

 
The winner of the Bluepharma | University of Coimbra Innovation Award 2017 is the scientific project
"ProREGEN"

 

Award Date: January 12 and March 2, 2018

Development: Mónica Sousa, Sara Sousa and Ana Rita Pinto Costa, from the Institute for Research and Innovation in Health Sciences (i3S) - University of Porto

 

"ProREGEN" is a therapy that intends to improve the regeneration of the nervous system, where the repair of the spinal cord is necessary, acting on lesions of the nervous system and neurodegenerative diseases, through the Profilin-1 (Pfn1) protein that regulates the cytoskeleton. The jury highlighted its originality, innovation, market viability and the potential value for society, which is why the first place amongst 23 competing projects was awarded.

Read more at Bluepharma News | University of Coimbra News
Watch video

 
The winner of the Bluepharma | University of Coimbra Innovation Award 2015 is the scientific project
"Bug-Killer"

 

Award Date: January 11 and February 29, 2016

Development: Doctor Lino Ferreira and Doctor Akhilesh Rai, from the Center for Neuroscience and Cell Biology (CNC) - Universty of Coimbra (UC)

 

"Bug-Killer" plans to develop a new biomedical formulation that combines antimicrobial properties and pro-regenerative, with high antimicrobial efficacy and antigenic and immunomodulatory properties. It aims to address a major public health problem worldwide, related to the lack of new drugs to combat microbial infections and a growing resistance to antibiotics.

Read more at Bluepharma News | University of Coimbra News

 
The winner of the Bluepharma | University of Coimbra Innovation Award 2013 is the scientific project
"Trifunctional antibodies and dendritic cell-based technologies: a combined approach to cancer immunotherapy"

 

Award Date: September 01 to October 31, 2013

Development: Researcher Paula Videira and researchers from the Faculty of Medical Sciences and the Faculty of Science and Technology of the Universidade Nova de Lisboa, the Portuguese Institute of Oncology of Porto and the Institute of Hygiene and Tropical Medicine

 

A equipa de Lisboa desenvolveu um anticorpo capaz de reconhecer o antígeno glicosídico, presente em mais de 80% dos carcinomas humanos, incluindo cancro da mama, cancro gástrico, cancro do pâncreas e cancro da bexiga e ausente em células normais. Este antigénio tumoral surge na fase inicial do tumor tornando-o um excelente candidato para atingir as fases iniciais de malignidade e assim para controlar a progressão da doença. O desenvolvimento de anticorpos que simultaneamente atacam as células cancerígenas e são reconhecidos e activam diferentes células do sistema imunitário, eliminando o tumor, traduzem uma nova estratégia de tratamento do cancro, que esteve na base da escolha desta candidatura.

Read more at Bluepharma News | SIC Notícias
Watch video